Citation tools

Perrone, Elisabetta et al "Long-term adverse events and survival of patients with neuroendocrine neoplasms (NEN) receiving peptide receptor radioligand therapy (PRRT) using 225Ac- and 225Ac-/177Lu-labeled (TANDEM) antagonist DOTA-LM3: A retrospective analysis." Journal of Nuclear Medicine 65.supplement 2 (2024): 242083. Web. 05 May. 2025.